Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

NCT04626791 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Acalabrutinib
DRUG: Bortezomib
DRUG: Cyclophosphamide
DRUG: Cytarabine
DRUG: Doxorubicin Hydrochloride
DRUG: Prednisone
BIOLOGICAL: Rituximab
BIOLOGICAL: Rituximab and Hyaluronidase Human

Sponsor

Academic and Community Cancer Research United

Collaborators

[object Object]